flavin-mononucleotide and Brain-Injuries

Autors determine the clinical effectiveness of including cytoflavin in intensive care of patients with severe combined traumatic brain injury. A prospective blind randomized controlled study was conducted on two groups involving 101 participants. In group I (58 patients), the intensive care was standard. In group II (43 patients), the intensive care included cytoflavin which was added beginning with the second day of the post-traumatic period. For this purpose, 10 ml of cytoflavin was dissolved in 200 ml of 10% aqueous solution of glucose and was administered intravenously at a speed of 140 drops (7 ml) per minute within 7 days. The use of cytoflavin in complex intensive care of severe combined traumatic brain injury within two days after injury (with the proper correction of blood circulation and respiration) reduced the number of multiple organ dysfunctions, the number is purulent-septic complications, the time of regress in multiple organ dysfunctions, and the reanimation period in intensive care department on the average by a factor of 1.4 - 1.6 (p < 0.005).

Topics: Adolescent; Adult; Aged; Brain Injuries; Critical Care; Drug Combinations; Female; Flavin Mononucleotide; Humans; Inosine Diphosphate; Male; Middle Aged; Neuroprotective Agents; Niacinamide; Prospective Studies; Succinates; Time Factors

A randomized prospective study of 191 patients with concomitant brain injury (CBI) of different severity has been carried out. All patients underwent surgery and received treatment in reanimation and intensive care departments. The main group consisted of 100 (52.4%) patients treated with cytoflavin in dosage 20-40 ml daily intravenously in drops during 10 days in addition to standard treatment. The comparison group included 91 (47.6%) patients who received standard treatment only. A positive effect of cytoflavin on clinical symptoms and laboratory characteristics of patients with CBI was identified. The decrease in severity measured with the APACHE II, higher activation of consciousness and improvement in the dynamics of neurological symptoms in these patients have resulted in the reduction in the duration of artificial lung ventilation and total hospital stay.

Topics: Adolescent; Adult; Brain Injuries; Critical Care; Drug Combinations; Energy Metabolism; Female; Flavin Mononucleotide; Homeostasis; Hospital Mortality; Humans; Inosine Diphosphate; Length of Stay; Male; Middle Aged; Niacinamide; Prospective Studies; Respiration, Artificial; Succinates; Treatment Outcome; Young Adult

Sixty outpatients, aged 18-50 years, with mild cranial-brain trauma (brain concussion, mild brain injury), occurred 21-180 days before the enrollment in the study, were examined. Patients of the main group received cytoflavin in dose 425 mg, 2 tablets twice a day during 25 days, patients of the control group received aminalon in dose 500 mg, 2 tablets 3 times a day during 25 days. The therapeutic efficacy was assessed on days 1, 30 and 60 with the battery of neuropsychological scales. The efficacy and safety of cytoflavin in the monotherapy of patients with remote consequences of mild cranial-brain trauma was shown. The effect of cytoflavin was developed significantly more rapidly compared to aminalon. There were positive changes on scales of pain severity, psychoemotional disorders (anxiety, depression, asthenia), sleep quality, autonomic dysfunctions as well as in the performance on neurocognitive tests assessing memory, sustained attention, information processing speed, productivity. The duration of using analgesics and sedatives as add-on drugs was reduced significantly. The drug remained effective till the 60th day after the 30 day withdrawal. Side-effects of cytoflavin (the short-term rise of arterial pressure, insomnia and abdominalgia) did not last long and no additional treatment, withdrawal or reduction of cytoflavin dose was needed.

Topics: Adolescent; Adult; Brain Injuries; Drug Combinations; Flavin Mononucleotide; gamma-Aminobutyric Acid; Humans; Inosine Diphosphate; Middle Aged; Niacinamide; Succinates; Treatment Outcome; Young Adult

To study the effectiveness of intraoperative administration of Cytoflavine for the prevention of ischemic brain injury during cerebral aneurysm (CA) clipping with temporary occlusion of the leading artery under general anesthesia.. The prospective cohort single-center study included 40 patients with CA ( the main group - 27 patients with intraoperative administration of cytoflavine; the comparison group -13 patients without use of cytoflavine), who underwent aneurism clipping with temporary occlusion of the afferent artery. We assesed the intraoperative state of the brain, the time of awakening and extubation of patients after surgery, neurological deficit and local ischemic changes in the area of surgery according to the CT of the brain in the early postoperative period, resuscitation bed-day and the relationship of these indicators with the duration of temporary occlusion of the afferent artery in the selected groups of patients.. In intergroup comparison, patients of the main group treated with intraoperative cytoflavin showed a reduction in the time of awakening (p=0.013) and the time of extubation (p=0.01) both with temporary occlusion of the afferent artery and in patients without temporary occlusion (p<0.05). The duration of resuscitation bed-day decreased in the main group of patients receiving intraoperatively cytoflavine (p=0.01), as well as in patients in the comparison group without temporary occlusion (p<0.05).. Temporary occlusion of the afferent artery with short intervals of vessel occlusion in combination with intraoperative intravenous administration of cytoflavine expands the tolerability to artery occlusion in patients operated in the 'cold' period, reduces the possibility of neurological deficit, reduces the recovery period and resuscitation bed-day after surgical clipping CA.. Цель исследования - изучение эффективности интраоперационного введения препарата цитофлавин для профилактики ишемического повреждения головного мозга при нейрохирургических операциях клипирования церебральной аневризмы (ЦА) с использованием временной окклюзии приводящей артерии в условиях общей анестезии. Материал и методы. В проспективное когортное одноцентровое исследование включены 40 пациентов с ЦА (основная группа - 27 больных с интраоперационным введением цитофлавина; группа сравнения - 13 пациентов без использования цитофлавина), оперированных открытым способом с плановым использованием методики временной окклюзии питающей аневризму артерии. Определяли интраоперационное состояние мозга, сроки пробуждения и экстубации больных после выполнения хирургического вмешательства, неврологический дефицит и локальные ишемические изменения в зоне оперативного вмешательства по данным СКТ головного мозга в раннем послеоперационном периоде, реанимационный койко-день и взаимосвязь этих показателей с длительностью временной окклюзии приводящей артерии в выделенных группах пациентов. Результаты. При межгрупповом сравнении у пациентов основной группы, получавших интраоперационно цитофлавин, отмечено сокращение сроков пробуждения (p=0,013) и экстубации (p=0,01) как с временной окклюзией питающей аневризму артерии, так и без временного клипирования приводящего сосуда (p<0,05). Продолжительность реанимационного койко-дня уменьшалась в основной группе пациентов, получавших интраоперационно препарат цитофлавин (p=0,01), а также у больных в группе сравнения без временного клипирования (p<0,05). Выводы. Временное клипирование питающей аневризму артерии с короткими интервалами окклюзии сосуда в сочетании с интраоперационным внутривенным введением цитофлавина расширяет переносимость окклюзии артерии у пациентов, оперированных в 'холодном' периоде, уменьшает возможности возникновения неврологического дефицита, сокращает сроки восстановительного периода и реанимационного койко-дня после оперативного лечения клипирования ЦА.

Topics: Brain; Brain Injuries; Brain Ischemia; Drug Combinations; Flavin Mononucleotide; Humans; Inosine Diphosphate; Intracranial Aneurysm; Intraoperative Care; Neuroprotective Agents; Neurosurgical Procedures; Niacinamide; Prospective Studies; Succinates; Suture Techniques

Results of the therapy of patients with toxicohypoxic encephalopathy diagnosis upon heavy poisoning by psychotropic substances are presented. It is established that administration of the antihypoxant cytoflavin provides for a substantial decrease in the extent of metabolic disorders related to the development of heavy hypoxia. The use of cytoflavin significantly decreases the degree of encephalopathy and favors faster and better recovery of the mnestic and other cognitive functions in patients upon heavy toxicohypoxic brain damage caused by acute poisoning.

Topics: Adult; Brain Injuries; Cognition Disorders; Drug Combinations; Female; Flavin Mononucleotide; Humans; Hypoxia, Brain; Inosine Diphosphate; Male; Niacinamide; Psychotropic Drugs; Succinates